Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Y. Metaxas"'
Autor:
G. Zarkavelis, A.L. Amylidi, C. Verbaanderd, N.I. Cherny, Y. Metaxas, E.G.E. de Vries, P. Zygoura, T. Amaral, K. Jordan, M. Strijbos, U. Dafni, N. Latino, M. Galotti, F. Lordick, R. Giuliani, F. Pignatti, G. Pentheroudakis
Publikováno v:
ESMO Open, 8(1):100604. BMJ PUBLISHING GROUP
Introduction: Off-label use of medicines is generally discouraged. However, several off-patent, low-cost cancer medicines remain off-label for indications in which they are commonly used in daily practice, supported by high-level evidence based on re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b3e5810361f54e84f5ca801bba6d3f
https://hdl.handle.net/11370/ea500612-1811-4e95-9549-8f63ee607dd5
https://hdl.handle.net/11370/ea500612-1811-4e95-9549-8f63ee607dd5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Miklos Pless, Eric I. Eboulet, Martina Schneider, Martin Früh, Patrizia Froesch, Sacha I. Rothschild, Y. Metaxas, Luciano Wannesson, Susanne Weindler, Michael Schwitter, Nathalie Baudoux, Alfredo Addeo, Alex Friedlaender, Wolf-Dieter Janthur, Henning Burmeister, Michael Mark, Markus Joerger, Christine Biaggi-Rudolf
Publikováno v:
Cancer Immunology, Immunotherapy. 70:1255-1262
The safety of first-line (1L) durvalumab in patients with advanced nonsmall-cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 (PS2) is unknown. This is an interim unplanned safety analysis of the study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::483a60c292e3b4e5ac92e13cf756c8d9
https://doi.org/10.1007/s00262-020-02757-8
https://doi.org/10.1007/s00262-020-02757-8
Autor:
M. Joerger, P. Knüsel, E. Alejandre-Lafont, Y. Metaxas, M.T. Mark, R.A.F. von Moos, K. Gysel, K. Eckhardt, J. Glaus Garzon, K-L. Koster, Y. Wittwer, S. Tissot, L. Flatz, L. Alleruzzo, S.K. Lam, D. Anderson, W. Chen, E. Baskin-Bey, T. Hode
Publikováno v:
Immuno-Oncology and Technology. 16:100306
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::247db33208dfabd4d5873eadd4970272
https://doi.org/10.1016/j.iotech.2022.100306
https://doi.org/10.1016/j.iotech.2022.100306
Autor:
K.D. Joode, A. Rojas Mora, R. Van Schaik, A. Zippelius, A.A.M. Van der Veldt, C.L. Gerard, H. Läubli, O.A. Michielin, R.A.F. von Moos, M. Joerger, M.P. Levesque, S. Aeppli, J. Mangana, C. Mangas, S. Meyer, S. Leoni-Parvex, R.H. Mathijssen, Y. Metaxas
Publikováno v:
Immuno-Oncology and Technology. 16:100124
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::637ee9f05dbc5f28c3159b4972a9d8f9
https://doi.org/10.1016/j.iotech.2022.100124
https://doi.org/10.1016/j.iotech.2022.100124
Autor:
A. Digklia, A. Kollar, M-N. Kronig, C. Britschgi, T. Rordorf, M. Joerger, F. Krasniqi, Y. Metaxas, I. Colombo, D. Dietrich, S. Chiquet, K. Ribi, C.A. Rothermundt
Publikováno v:
Annals of Oncology. 33:S1230
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3aee5a314cebeab98a0eb870f50d5186
https://doi.org/10.1016/j.annonc.2022.07.1598
https://doi.org/10.1016/j.annonc.2022.07.1598
Autor:
Silvia Stuedeli, Cristiana Sessa, Thomas Kaindl, D. Hess, Nicole Levy, Y. Metaxas, Anastasios Stathis, Patrice Larger, Heidi Lane, Roger von Moos, Peter Hafner, Mara Mantiero, Marc Engelhardt, Michael Mark, Markus Joerger, Matthias Volden
Publikováno v:
Investigational New Drugs
SummaryPurpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when administered as a 2-h infusion, but its use was limited by vascular toxicity. We investigated an alternative dosing str
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc8b1fc2bd29aa41bfe70b3c532bb7b
http://europepmc.org/articles/PMC7340672
http://europepmc.org/articles/PMC7340672
Autor:
Carmen Kahatt, Cristiana Sessa, Salvador Fudio, Martin Forster, Ruth Plummer, Anastasios Stathis, Vicente Alfaro, Roger von Moos, Y. Metaxas, Ali Zeaiter
Publikováno v:
Investigational new drugs. 40(1)
Background In vitro/in vivo data showed synergism of cisplatin and lurbinectedin in ovarian cancer cells and grafts. This phase I trial investigated the recommended phase II dose (RD) of cisplatin and lurbinectedin combination, with (Group A) or with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7c09fa30249552e0edfe7bc468289b8
https://pubmed.ncbi.nlm.nih.gov/34453241
https://pubmed.ncbi.nlm.nih.gov/34453241
Autor:
Christian Britschgi, N. Cantoni, N. Mach, R. von Moos, S. Stettler, D. Koeberle, C. Kopp, Miklos Pless, Christoph Renner, Andreas M. Schmitt, Clemens B. Caspar, Stefanie Hayoz, O. Michielin, Anastasios Stathis, R. Malval, J. Schulz, Markus Joerger, Khalil Zaman, Y. Metaxas, Daniel C. Betticher
Publikováno v:
Annals of Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f91972ace966705b39034f2fc7b1ac7
https://doi.org/10.1016/j.annonc.2021.08.1563
https://doi.org/10.1016/j.annonc.2021.08.1563